Do GLP-1 drugs protect your heart?

The diabetes evidence came first

GLP-1 agonists were licensed for type 2 diabetes long before obesity, and regulators required cardiovascular safety trials. Those trials did not merely show safety — they showed benefit. Pooled analyses across the programme found consistent reductions in major adverse cardiovascular events, cardiovascular death and kidney outcomes, in the region of 12-14% relative risk reduction for MACE ^[5][6]. REWIND extended the finding to a population with lower baseline cardiovascular risk ^[8].

Cardiovascular benefit in type 2 diabetes

SELECT: the trial that changed the framing

SELECT enrolled adults with overweight or obesity and established cardiovascular disease but without diabetes, and randomised them to semaglutide 2.4 mg or placebo for around four years. It found roughly a 20% reduction in the primary composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke.

The subsequent meta-analytic work incorporating SELECT confirms the direction and magnitude ^[1]. A pre-specified analysis in the heart failure subgroup found benefit there too ^[7].

Why it mattered: it decoupled the cardiovascular benefit from glycaemic control. Whatever is driving the event reduction, it is not simply "better diabetes management" — because these participants did not have diabetes.

How much is the weight loss doing?

This is the genuinely open question. Candidate explanations include weight loss itself, blood pressure reduction, direct anti-inflammatory effects on the vessel wall, and improved kidney function. The timing of divergence in the event curves has been used to argue for a direct effect beyond weight, but the trials were not designed to separate these and the honest answer is that the mechanism is unresolved.

Kidneys

The kidney findings have strengthened considerably. Pooled analysis in populations with established chronic kidney disease shows benefit on both kidney and cardiovascular endpoints ^[2], consistent with the earlier class-wide meta-analyses ^[5]. Tirzepatide showed kidney benefit against insulin glargine in SURPASS-4. There is more detail on the non-weight uses page.

Combining with SGLT2 inhibitors

A meta-analysis using SMART methodology examined SGLT2 inhibitors with and without GLP-1 agonists and found the benefits are not redundant ^[3]. For people with type 2 diabetes and cardiovascular or kidney disease, the two classes together are increasingly the standard rather than a choice between them.

The tirzepatide picture

Tirzepatide has a pre-specified meta-analysis showing no cardiovascular harm signal ^[4] and a direct comparison against dulaglutide reporting cardiovascular outcomes in type 2 diabetes ^[9]. It does not yet have a SELECT-equivalent — a dedicated outcome trial in a non-diabetic obese population — which is the main reason semaglutide retains an evidential edge on this specific endpoint despite losing on weight loss.

Common questions